Anxiety, depression and stress tension screening in patients with rheumatic and musculoskeletal diseases at the onset of the 2019 coronavirus disease (COVID-19) pandemic

The aim - screening of anxiety, depression and stress in patients with rheumatic and musculoskeletal diseases (RMD) and medical workers at the beginning of the COVID-19.Material and methods. 150 patients (men/women: 39 (26.0%)/111 (74.0%); mean age - 43.2±16.1 years) with RMD, hospitalized at the V....

Full description

Bibliographic Details
Main Authors: A. B. Borisova, T. A. Lisitsyna, D. Yu. Veltishchev, E. L. Nasonov
Format: Article
Language:Russian
Published: IMA PRESS LLC 2021-12-01
Series:Научно-практическая ревматология
Subjects:
Online Access:https://rsp.mediar-press.net/rsp/article/view/3101
_version_ 1826555862285549568
author A. B. Borisova
T. A. Lisitsyna
D. Yu. Veltishchev
E. L. Nasonov
author_facet A. B. Borisova
T. A. Lisitsyna
D. Yu. Veltishchev
E. L. Nasonov
author_sort A. B. Borisova
collection DOAJ
description The aim - screening of anxiety, depression and stress in patients with rheumatic and musculoskeletal diseases (RMD) and medical workers at the beginning of the COVID-19.Material and methods. 150 patients (men/women: 39 (26.0%)/111 (74.0%); mean age - 43.2±16.1 years) with RMD, hospitalized at the V.A. Nasonova Research Institute of Rheumatology (Moscow) from July to November 2020, and 32 relatively healthy medical workers (men/women: 3 (9.38%)/29 (90.6%), mean age - 40.7±14.6 years) as a control group was included in the study. The Hospital Anxiety and Depression Scale (HADS) and the Depression Anxiety and Stress Scale - 21 Items (DASS-21) were used for anxiety, depression and stress screening. Results. Frequency of anxiety-depressive spectrum disorders in patients with RMD was 48% (according to DASS-21) and 27.2% (according to HADS), which did not differ significantly from the control group - 46.9% and 18.8% respectively. According to the DASS-21, patients with systemic sclerosis were significantly more likely to have a combination of clinically significant anxiety, depression and stress compared to healthy control (6 (46.2%) vs 4 (12.5%); p=0.02) and patients with spondyloarthritis (6 (46.2% vs 5 (16.1%); p=0.045). The severity of anxiety was significantly higher among patients with RMD - systemic lupus erythematosus, primary Sjogren's syndrome and systemic sclerosis, according to both scales. The severity of depression, anxiety and stress was significantly higher in women with RMD, rural residents and patients taking moderate and high doses of glucocorticoids. The pathological stress level was experienced by younger medical workers (27.5±5.45 vs 45.8±13.8 years; p=0.001). The transferred coronavirus infection did not lead to an increase in the severity of depression, anxiety and stress tension among patients, however, among medical workers, the frequency of clinically significant anxiety (4 (57.1%) vs 6 (24%)) and stress (3 (42.8%) vs 5 (20%)) was 2.2-2.9 times higher in those who have been ill. When compared with the results of the similar screening by HADS in 2012, the proportion of RМD-patients with clinically significant anxiety and depression over the past 8 years and in connection with the pandemic COVID-19 has not significantly changed.Conclusion. A new threat to health, isolation and uncertainty at the beginning of the COVID-19 were an additional stressful factor for patients with RМD, however, given the high background prevalence of low-severity chronic depression with frequent onset before RМD, the factor of the COVID-19 is not a key factor in provoking mental disorders.
first_indexed 2024-04-09T22:21:24Z
format Article
id doaj.art-1c00ef619d4c4f748cfbb6657bea4474
institution Directory Open Access Journal
issn 1995-4484
1995-4492
language Russian
last_indexed 2025-03-14T08:03:33Z
publishDate 2021-12-01
publisher IMA PRESS LLC
record_format Article
series Научно-практическая ревматология
spelling doaj.art-1c00ef619d4c4f748cfbb6657bea44742025-03-02T13:23:50ZrusIMA PRESS LLCНаучно-практическая ревматология1995-44841995-44922021-12-0159667668310.47360/1995-4484-2021-676-6832765Anxiety, depression and stress tension screening in patients with rheumatic and musculoskeletal diseases at the onset of the 2019 coronavirus disease (COVID-19) pandemicA. B. Borisova0T. A. Lisitsyna1D. Yu. Veltishchev2E. L. Nasonov3Moscow Research Institute of Psychiatry -the Branch of the «National Medical Research Center for Psychiatry and Narcology» of the Ministry of Health of the Russian FederationV.A. Nasonova Research Institute of RheumatologyMoscow Research Institute of Psychiatry -the Branch of the «National Medical Research Center for Psychiatry and Narcology» of the Ministry of Health of the Russian Federation; N.I. Pirogov Russian National Research Medical UniversityV.A. Nasonova Research Institute of Rheumatology; I.M. Sechenov First Moscow State Medical University of the Ministry of Health Care of Russian Federation (Sechenov University)The aim - screening of anxiety, depression and stress in patients with rheumatic and musculoskeletal diseases (RMD) and medical workers at the beginning of the COVID-19.Material and methods. 150 patients (men/women: 39 (26.0%)/111 (74.0%); mean age - 43.2±16.1 years) with RMD, hospitalized at the V.A. Nasonova Research Institute of Rheumatology (Moscow) from July to November 2020, and 32 relatively healthy medical workers (men/women: 3 (9.38%)/29 (90.6%), mean age - 40.7±14.6 years) as a control group was included in the study. The Hospital Anxiety and Depression Scale (HADS) and the Depression Anxiety and Stress Scale - 21 Items (DASS-21) were used for anxiety, depression and stress screening. Results. Frequency of anxiety-depressive spectrum disorders in patients with RMD was 48% (according to DASS-21) and 27.2% (according to HADS), which did not differ significantly from the control group - 46.9% and 18.8% respectively. According to the DASS-21, patients with systemic sclerosis were significantly more likely to have a combination of clinically significant anxiety, depression and stress compared to healthy control (6 (46.2%) vs 4 (12.5%); p=0.02) and patients with spondyloarthritis (6 (46.2% vs 5 (16.1%); p=0.045). The severity of anxiety was significantly higher among patients with RMD - systemic lupus erythematosus, primary Sjogren's syndrome and systemic sclerosis, according to both scales. The severity of depression, anxiety and stress was significantly higher in women with RMD, rural residents and patients taking moderate and high doses of glucocorticoids. The pathological stress level was experienced by younger medical workers (27.5±5.45 vs 45.8±13.8 years; p=0.001). The transferred coronavirus infection did not lead to an increase in the severity of depression, anxiety and stress tension among patients, however, among medical workers, the frequency of clinically significant anxiety (4 (57.1%) vs 6 (24%)) and stress (3 (42.8%) vs 5 (20%)) was 2.2-2.9 times higher in those who have been ill. When compared with the results of the similar screening by HADS in 2012, the proportion of RМD-patients with clinically significant anxiety and depression over the past 8 years and in connection with the pandemic COVID-19 has not significantly changed.Conclusion. A new threat to health, isolation and uncertainty at the beginning of the COVID-19 were an additional stressful factor for patients with RМD, however, given the high background prevalence of low-severity chronic depression with frequent onset before RМD, the factor of the COVID-19 is not a key factor in provoking mental disorders.https://rsp.mediar-press.net/rsp/article/view/3101covid-19anxietydepressionstressrheumatic musculoskeletal diseasesmental disorders
spellingShingle A. B. Borisova
T. A. Lisitsyna
D. Yu. Veltishchev
E. L. Nasonov
Anxiety, depression and stress tension screening in patients with rheumatic and musculoskeletal diseases at the onset of the 2019 coronavirus disease (COVID-19) pandemic
Научно-практическая ревматология
covid-19
anxiety
depression
stress
rheumatic musculoskeletal diseases
mental disorders
title Anxiety, depression and stress tension screening in patients with rheumatic and musculoskeletal diseases at the onset of the 2019 coronavirus disease (COVID-19) pandemic
title_full Anxiety, depression and stress tension screening in patients with rheumatic and musculoskeletal diseases at the onset of the 2019 coronavirus disease (COVID-19) pandemic
title_fullStr Anxiety, depression and stress tension screening in patients with rheumatic and musculoskeletal diseases at the onset of the 2019 coronavirus disease (COVID-19) pandemic
title_full_unstemmed Anxiety, depression and stress tension screening in patients with rheumatic and musculoskeletal diseases at the onset of the 2019 coronavirus disease (COVID-19) pandemic
title_short Anxiety, depression and stress tension screening in patients with rheumatic and musculoskeletal diseases at the onset of the 2019 coronavirus disease (COVID-19) pandemic
title_sort anxiety depression and stress tension screening in patients with rheumatic and musculoskeletal diseases at the onset of the 2019 coronavirus disease covid 19 pandemic
topic covid-19
anxiety
depression
stress
rheumatic musculoskeletal diseases
mental disorders
url https://rsp.mediar-press.net/rsp/article/view/3101
work_keys_str_mv AT abborisova anxietydepressionandstresstensionscreeninginpatientswithrheumaticandmusculoskeletaldiseasesattheonsetofthe2019coronavirusdiseasecovid19pandemic
AT talisitsyna anxietydepressionandstresstensionscreeninginpatientswithrheumaticandmusculoskeletaldiseasesattheonsetofthe2019coronavirusdiseasecovid19pandemic
AT dyuveltishchev anxietydepressionandstresstensionscreeninginpatientswithrheumaticandmusculoskeletaldiseasesattheonsetofthe2019coronavirusdiseasecovid19pandemic
AT elnasonov anxietydepressionandstresstensionscreeninginpatientswithrheumaticandmusculoskeletaldiseasesattheonsetofthe2019coronavirusdiseasecovid19pandemic